Literature DB >> 17898737

HIV vaccine failure prompts Merck to halt trial.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17898737     DOI： 10.1038/449390c

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  45 in total

1.  For protection from HIV-1 infection, more might not be better: a systematic analysis of HIV Gag epitopes of two alleles associated with different outcomes of HIV-1 infection.

Authors:  Ma Luo; Christina A Daniuk; Tamsir O Diallo; Rupert E Capina; Joshua Kimani; Charles Wachihi; Makubo Kimani; Thomas Bielawny; Trevor Peterson; Mark G R Mendoza; Sandra Kiazyk; T Blake Ball; Francis A Plummer
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  HIV/AIDS therapy and prevention: The two solitudes.

Authors:  Jocelyne Piret; Michel G Bergeron
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

3.  Vaccine outlooks. After negative publicity and a series of setbacks over HIV/AIDS and influenza, the prospects for research on new vaccines are improving.

Authors:  Philip Hunter
Journal:  EMBO Rep       Date:  2010-10       Impact factor: 8.807

4.  Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.

Authors:  Hubert Gaertner; Fabrice Cerini; Jean-Michel Escola; Gabriel Kuenzi; Astrid Melotti; Robin Offord; Irène Rossitto-Borlat; Rebecca Nedellec; Janelle Salkowitz; Guy Gorochov; Donald Mosier; Oliver Hartley
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-12       Impact factor: 11.205

5.  A novel self-replicating chimeric lentivirus-like particle.

Authors:  Christy K Jurgens; Kelly R Young; Victoria J Madden; Philip R Johnson; Robert E Johnston
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

6.  Can an immune-regulatory vaccine prevent HIV infection?

Authors:  Tobias Boettler; Edecio Cunha-Neto; Jorge Kalil; Matthias von Herrath
Journal:  Expert Rev Anti Infect Ther       Date:  2012-03       Impact factor: 5.091

Review 7.  Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).

Authors:  Michael Vaine; Shan Lu; Shixia Wang
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

8.  CD4+ target cell availability determines the dynamics of immune escape and reversion in vivo.

Authors:  Janka Petravic; Liyen Loh; Stephen J Kent; Miles P Davenport
Journal:  J Virol       Date:  2008-02-13       Impact factor: 5.103

9.  Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge.

Authors:  Nancy A Wilson; Brandon F Keele; Jason S Reed; Shari M Piaskowski; Caitlin E MacNair; Andrew J Bett; Xiaoping Liang; Fubao Wang; Elizabeth Thoryk; Gwendolyn J Heidecker; Michael P Citron; Lingyi Huang; Jing Lin; Salvatore Vitelli; Chanook D Ahn; Masahiko Kaizu; Nicholas J Maness; Matthew R Reynolds; Thomas C Friedrich; John T Loffredo; Eva G Rakasz; Stephen Erickson; David B Allison; Michael Piatak; Jeffrey D Lifson; John W Shiver; Danilo R Casimiro; George M Shaw; Beatrice H Hahn; David I Watkins
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

10.  Acute mucosal pathogenesis of feline immunodeficiency virus is independent of viral dose in vaginally infected cats.

Authors:  Kristina E Howard; Stacie K Reckling; Erin A Egan; Gregg A Dean
Journal:  Retrovirology       Date:  2010-01-19       Impact factor: 4.602
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.